Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial

INTRODUCTION: Cardiac transplantation (CTx) is a life-saving operation that can improve the quality and length of a recipient’s life. Immunosuppression medication, required to prevent rejection, can result in adverse metabolic and renal effects. Clinically significant complications include metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Raven, Lisa Mary, Muir, Christopher A, Kessler Iglesias, Cassia, Bart, Nicole K, Muthiah, Kavitha, Kotlyar, Eugene, Macdonald, Peter, Hayward, Christopher S, Jabbour, Andrew, Greenfield, Jerry R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069602/
https://www.ncbi.nlm.nih.gov/pubmed/36990488
http://dx.doi.org/10.1136/bmjopen-2022-069641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069602/
https://www.ncbi.nlm.nih.gov/pubmed/36990488
http://dx.doi.org/10.1136/bmjopen-2022-069641

Ejemplares similares